The purpose of this meta-analysis was to examine the efficacy of maintenance treatments for bipolar disorder. Placebo-controlled or active comparator bipolar maintenance clinical trials of o6 months' duration with at least 15 patients/treatment group were identified using Medline, EMBASE, clinicaltrials.gov, and Cochrane databases (1993 to July 2010). The main outcome measure was relative risk for relapse for patients in remission. Twenty trials (5364 patients) were identified. Overall, lithium and quetiapine were the most studied agents (eight and five trials, respectively). The majority of studies included patients who had previously responded to treatment for an acute episode. All interventions, with the exception of perphenazine+mood stabilizer, showed a relative risk for manic/mixed or depressive relapse below 1.0, although there was variation in the statistical significance of the findings vs. placebo. No monotherapy was associated with a significantly reduced risk for both manic/mixed and depressed relapse. Of the combination treatments, only quetiapine+lithium/divalproex, was associated with a significantly reduced risk vs. comparator (placebo+lithium/valproate) for relapse at both the manic/mixed and depressed poles of bipolar illness. Limitations for the analysis include differences in study durations and definitions of relapse. In conclusion, available maintenance therapies show considerable variation in efficacy. The efficacy of lithium and divalproex has been confirmed, but newer therapies, such as a number of atypical antipsychotics were also shown to be effective in bipolar disorder. Efficacy of all maintenance interventions needs to be balanced against the safety and tolerability profiles of individual agents.
Introduction
Bipolar disorder is a major mental health issue associated with considerable morbidity and mortality (Hirschfeld & Vornik, 2005) . It is characterized by recurrent episodes of mania or hypomania and depression, separated by periods of relatively normal behaviour (Kasper, 2003 ; Oswald et al. 2007) . In some people, however, symptoms of mania and depression may occur together in what is called a mixed bipolar state. Treatments are available that can stabilize the acute mood swings -mania, hypomania, depression or mixed states -in bipolar disorders. However, because it is a recurrent illness, long-term prophylactic maintenance treatment is usually recommended (Suppes et al. 1991) .
The primary therapeutic objective of maintenance therapy is to prevent relapse and recurrence of acute mood events, but as patients are likely to receive maintenance treatment for extensive periods of time, the tolerability of these agents is also an important consideration. A variety of guidelines exist for bipolar disorders, covering both management of acute mood episodes and long-term prophylaxis (APA, 2002 ; Goodwin, 2003 ; Grunze et al. 2010 ; International Consensus Group, 2008 ; NICE, 2006 ; Scottish Intercollegiate Guidelines Network, 2005 ; Suppes et al. 2005 ; Yatham et al. 2009 ). The majority of guidelines include lithium in their recommendations for first-line maintenance therapy (APA, 2002 ; Goodwin, 2003 ; NICE, 2006 ; Scottish Intercollegiate Guidelines Network, 2005 ; Yatham et al. 2009 ). Recommendations for other first-line maintenance therapies vary, but usually include divalproex or lamotrigine, and sometimes olanzapine (Fountoulakis et al. 2005) . In contrast to most guidelines, those provided by the Texas Implementation of Medication Algorithms recommend different approaches to bipolar maintenance treatment, depending on the nature of the preceding acute episode (Suppes et al. 2005) . After an episode of mania or hypomania, lithium or divalproex are recommended, whereas following an acute episode of depression, lamotrigine is recommended, either as monotherapy or in combination with an antimanic agent such as lithium or divalproex (Suppes et al. 2005) . It is likely that there are many reasons underlying the variations in guidelines, including the paucity of controlled head-to-head trials on which to base recommendations, differences in the availability of pharmacological products, and differences in personal experiences and opinions. Furthermore, variation may reflect the rapidly changing armamentarium of agents available for bipolar maintenance, which can result in guidelines becoming outdated . Guidelines that are frequently updated, or that have been recently updated, will be based upon different data than those for which an update is due.
In the absence of randomized head-to-head clinical trials of available therapies, physicians, healthcare providers, and organizations involved in drafting guidelines must rely on comparative data obtained from systematic reviews and meta-analyses when making treatment decisions and recommendations. A number of such analyses have been conducted on maintenance therapies for bipolar disorders (Bowden et al. 2000a ; Chou & Fazzio, 2006 ; Derry & Moore, 2007 ; Grunze et al. 2004 ; Hellewell, 2006 ; Muzina & Calabrese, 2005 ; Rybakowski, 2005 ; Sachs & Thase, 2000 ; Smith et al. 2007 ). In the past, these analyses have provided useful information regarding the appropriate maintenance treatment for bipolar disorder ; however, some analyses have included only selected drug classes, which limits interpretation of the findings in the context of available therapies (Bowden et al. 2000a ; Derry & Moore, 2007 ; Grunze et al. 2004 ; Hellewell, 2006 ; Muzina & Calabrese, 2005 ; Rybakowski, 2005 ; Sachs & Thase, 2000) . Moreover, with the introduction of new therapies and publications of new trials of existing therapies, these analyses now need updating.
The most recently published comprehensive analysis on maintenance therapies was conducted by Smith et al. (2007) ; however, the cut-off date for inclusion was March 2005. Since this time, there have been many developments in the field of bipolar disorder, including new placebo-controlled trials assessing not only traditional maintenance therapies, such as lithium, but also newer options such as aripiprazole, long-acting risperidone, olanzapine, oxcarbazepine, quetiapine and ziprasidone. The introduction of new therapies for bipolar disorder -with different mechanisms of action and indications for both acute and maintenance treatment -raises questions about its optimal management. For example : Is there a rationale for distinguishing between drugs with different mechanisms of action as maintenance treatment options? Do any drugs show efficacy against the recurrence of manic/ mixed and depressed mood events (that is to say at both poles of bipolar illness)?
The objective of the current analysis was to determine the relative efficacy of pharmacological therapy in the maintenance treatment of bipolar disorder using evidence from independent clinical trials. In addition, we also consider the findings in the context of the questions outlined above.
Methods

Population
The intended analysis population consisted of adults (aged o18 yr) with a diagnosis of bipolar disorder. Both monotherapies and combination therapies, used as bipolar maintenance or relapse/recurrence prevention, were included in the meta-analysis.
Data sources
We searched Medline (1993 to May 2010 ), EMBASE (1993 to May 2010 and the Cochrane Library. We supplemented this by searching reference lists of identified trials and reviews. The language of publication was restricted to English. In the first instance we used the search term : bipolar AND (maintenance OR prophylaxis OR prevention OR preventive OR recurrence OR relapse) AND randomized AND trial. To capture additional maintenance trials with bipolar mania and related symptoms as index (initial) episode the following search string was also used : bipolar AND (mania OR manic OR cyclothymic OR hypomania OR rapid cycling) AND randomized AND trial. Different variants and spellings were tested whenever relevant.
A sequential search procedure was used. The first step was a search that combined typical key words for the indication and clinical trials. As a second step, the indication was combined with individual drug names : carbamazepine, valproate/divalproex/valproic acid, clonazepam, phenytoin, oxcarbazepine, licarbazepine, eslicarbazepine, gabapentin, levetiracetam, pregabalin, tiagabine, lamotrigine, topiramate, zonisamide, and retigabine, amisulpride, aripiprazole, clozapine, olanzapine, olanzapine+fluoxetine, quetiapine immediate release (IR) and extended release (XR), risperidone, risperidone injection (long-acting), haloperidol, chlorpromazine, pimozide, perphenazine, flupent(h)ixol, ziprasidone, asenapine, paliperidone, bifeprunox, lurasidone and zotepine. Antidepressants : paroxetine, fluoxetine, sertraline, citalopram, escitalopram, bupropion, venlafaxine, duloxetine, desvenlafaxine, imipramine, moclobemide, mirtazapine, tranylcypromine and agomelatine. Other : pramipexole, modafinil, inositol, tamoxifen and omega-3 fatty acids.
Eligibility criteria comprised : double-blind controlled studies (having either a placebo or active comparator), a duration of at least 6 months, and a minimum of 15 patients per treatment arm. These duration and sample sizes are recommended by regulatory agencies or required for conformational statistical testing.
Data extraction and outcomes
Two reviewers decided whether individual studies met the inclusion criteria. A standardized form, which included patient and study characteristics, outcome measures, and study results, was used to independently extract data from the selected studies. Data from intention-to-treat analyses (where available) and outcome data at the longest available follow-up were analysed.
Results are presented for relative risk (RR) of relapse for patients in remission and all-cause discontinuation during the randomized phase.
Data synthesis
The outcomes were combined in a meta-analysis. Binary outcomes (RR) were pooled by risk ratios using the Mantel-Haenszel method (Sutton et al. 2000) .
Heterogeneity between studies was measured with the x 2 test and the I 2 score. The I 2 score measures the proportion of heterogeneity in individual studies that cannot be explained by chance (Higgins & Thompson, 2002 ; Higgins et al. 2003) . It ranges between 0 % and 100 %, with lower values representing less heterogeneity. A high value reflects genuine differences between the results of the studies, while a low value reflects differences compatible with chance alone (Higgins et al. 2003) . If the x 2 test indicated heterogeneity, the random-effects analysis was performed using DerSimonian and Laird methods (DerSimonian & Laird, 1986) .
Statistical software
All calculations were performed with the general purpose statistical software package Stata version 10.2 (StataCorp LP, USA). The METAN package of Stata was used for performing the meta-analyses.
Results
After screening, 226 publications were identified through the combined search strategies, and we identified 21 trials, with a combined total of 5364 participants that fulfilled the inclusion criteria (Bowden et al. 2000b Calabrese et al. 2000 Calabrese et al. , 2003 Calabrese et al. , 2005 Greil et al. 1997 ; Hartong et al. 2003 ; Keck et al. 2007 ; Macfadden et al. 2009 ; McElroy et al. 2008 ; Quiroz et al. 2010 ; Suppes et al. 2009 ; Tohen et al. 2003 Tohen et al. , 2004 Tohen et al. , 2005 Tohen et al. , 2006 Vieta et al. 2008a, b ; Young et al. 2008 ; Zarate & Tohen, 2004) . Table 1 shows details of all trials included in the analysis.
We identified : one trial each for aripiprazole (Keck et al. 2007) , olanzapine+mood stabilizer , oxcarbazepine+lithium (Vieta et al. 2008a) , perphenazine+mood stabilizer (Zarate & Tohen, 2004) , risperidone long-acting injectable monotherapy (Quiroz et al. 2010) , risperidone long-acting injectable+mood stabilizer (Macfadden et al. 2009 ) and ziprasidone+mood stabilizer ; two trials for carbamazepine (Greil et al. 1997 ; Hartong et al. 2003) and quetiapine+mood stabilizer (Suppes et al. 2009 ; Vieta et al. 2008 b) and quetiapine monotherapy Young et al. 2008) ; three trials each for divalproex (Bowden et al. 2000a, b ; Greil et al. 1997 ; Tohen et al. 2003) , lamotrigine Calabrese et al. 2000 Calabrese et al. , 2003 and olanzapine (Tohen et al. 2003 (Tohen et al. , 2005 (Tohen et al. , 2006 ; and eight trials for lithium (Bowden et al. 2000 (Bowden et al. b, 2003 Calabrese et al. 2003 Calabrese et al. , 2005 Greil et al. 1997 ; Hartong et al. 2003 ; Tohen et al. 2005 ; Vieta et al. 2008a) . BPRS, Brief Psychiatric Rating Scale ; CGI-S, Clinical Global Impression -Severity ; CGI-C, Clinical Global Impression -Change ; CI, confidence interval ; GAF, global assessment of functioning ; HAMD, Hamilton Rating Scale for Depression ; IR, insufficient response ; MADRS, Montgomery-Å sberg Depression Rating Scale ; MRS, Mania Rating Scale ; TEM, treatment-emergent mania ; YMRS, Young Mania Rating Scale. a While every effort has been made to provide consistent data, variations in individual publications precluded the ability to provide consistency across all studies. b Differences in total patient numbers between the outcomes and discontinuations columns reflects differences in datasets. In general, the intention-to-treat population is used to calculate discontinuations, whereas the efficacy datasets include only patients who received at least one dose of medication.
The length of follow-up was 26 wk in three studies Calabrese et al. 2000 ; Zarate & Tohen, 2004) , between 47 and 52 wk in eight studies (Bowden et al. 2000b ; Macfadden et al. 2009 ; McElroy et al. 2008 ; Tohen et al. 2003 Tohen et al. , 2005 Tohen et al. , 2006 Vieta et al. 2008a ; Young et al. 2008) , between 72 and 80 wk in four studies Calabrese et al. 2003 Calabrese et al. , 2005 Tohen et al. 2004 ) and between 100 and 130 wk in six studies (Greil et al. 1997 ; Hartong et al. 2003 ; Keck et al. 2007 ; Quiroz et al. 2010 ; Suppes et al. 2009 ; Vieta et al. 2008b) . Median follow-up among the 21 studies was 52 wk, and mean follow-up was 68 wk. The majority of studies included a ' stabilization phase ' during which patients received treatment for an acute episode, and only those patients who responded to treatment were permitted to continue in the maintenance analysis. The index episodes in the acute treatment phases differed for individual studies, which may have influenced the findings (Table 2) .
A number of studies were excluded from the metaanalytical calculations because they did not include a placebo group, and used different comparators Greil et al. 1997 ; Hartong et al. 2003 ; Tohen et al. 2003 Tohen et al. , 2005 .
Efficacy relative to comparator
RR for relapse of any mood episode
The combined evidence for both manic and depressive relapses is shown in Figs 1 a and 1 b. All monotherapies had RRs significantly different from 1.0, favouring treatment. The overall estimate of the RR of any mood episode relapse compared to comparator (placebo) was 0.68 [95 % confidence interval (CI) 0.60-0.77, p<0.001], which is of the same order of magnitude as the overall RR for the individual events in maintenance treatment (shown below). The heterogeneity was moderate with an I 2 score of 52.3 %. Among the combination therapies, oxcarbazepine+ lithium, quetiapine+lithium/divalproex, risperidone+mood stabilizer, and ziprasidone+lithium/ divalproex had RRs significantly different from 1.0, favouring treatment. The overall estimate of the RR of any mood relapse for combination therapy compared to comparator [lithium (Vieta et al. 2008a) ; lithium/ divalproex Suppes et al. 2009 ; Tohen et al. 2004 ; Vieta et al. 2008b) ; mood stabilizer (Macfadden et al. 2009 ; Zarate & Tohen, 2004) ] was 0.49 (95 % CI 0.39-0.61, p<0.001). The heterogeneity was moderate with an I 2 score of 50.3 %. The point estimate for quetiapine+lithium/divalproex was the lowest with a RR of 0.38 (95 % CI 0.32-0.46). Quetiapine, however, represented a large part of the evidence for the RR of mood relapse in bipolar maintenance with 47 % of the weight in the overall estimate for combination therapy.
RR for manic/mixed relapse
All of the therapies -both monotherapy and combination -were found to have a RR for manic/mixed Studies without placebo comparator were excluded from the analysis Greil et al. 1997 ; Hartong et al. 2003 ; Tohen et al. 2003 Tohen et al. , 2005 .
relapse that was below 1.0, although significance vs. placebo or comparator varied among treatments (Figs 2 a, 2b) . The magnitude of the reduction in risk vs. placebo also varied between studies. Divalproex, lamotrigine, lithium and quetiapine monotherapy all had CIs extending beyond 1.0. The point estimate in one of the two studies concerning lamotrigine was below 1.0 , but both studies had quite wide CIs with the upper confidence limit for the RR being above 1.0 Calabrese et al. 2003) . A similar finding was observed for 300 mg quetiapine, with one point estimate below 1.0 ) and the other above 1.0 (Young et al. 2008) . As with lamotrigine, both studies had quite wide CIs with the upper confidence limit for the RR being above 1.0 Young et al. 2008) . The overall estimate of the RR of manic/mixed relapse compared to placebo was 0.65 (95 % CI 0.51-0.84) for monotherapy (p=0.001). The heterogeneity was moderate with an I 2 score of 56.6 %. Of the combination treatments, only quetiapine+ lithium/divalproex, long-acting risperidone+mood stabilizer, and ziprasidone+lithium/divalproex had RRs for manic/mixed relapse vs. their comparator treatments (lithium/divalproex and mood stabilizer, respectively) that were significantly below 1.0 (RR 0.39, 95 % CI 0.30-0.52, p<0.001 ; RR 0.40, 95 % CI 0.18-0.90, p=0.026 ; RR 0.39, 95 % CI 0.19-0.83, p=0.014, respectively) (Fig. 2 b) . The overall estimate of the RR of manic/mixed relapse compared to comparator [lithium (Vieta et al. 2008a) ; lithium/ divalproex Suppes et al. 2009 ; Tohen et al. 2004 ; Vieta et al. 2008b) ; mood stabilizer (Bowden et al. 2000b ; Zarate & Tohen, 2004) ] was 0.42 (95 % CI 0.33-0.53, p<0.001) for combination therapy (Fig. 2 b) . The heterogeneity was low with an I 2 score of 0 % (scores lower than zero are assigned the value zero).
RR for depressive relapse
The point estimates for all monotherapies except longacting injectable (LAI) risperidone were below 1.0 ; however, only divalproex (p=0.013), and quetiapine monotherapy (p=0.004 for 300 mg/d and p=0.002 for 600 mg/d) had RRs for relapse to a depressive episode that were significantly below 1.0 (Fig. 3 a) . The overall estimate of the RR of depressive relapse for monotherapy compared to placebo was 0.70 (95 % CI 0.58-0.85), which is of a similar order of magnitude as the overall RR for manic/mixed relapse in maintenance treatment. The heterogeneity was moderate with an I 2 score of 45.5 %. The overall estimate of the RR of depressive relapse for combination therapy compared to comparator [lithium (Vieta et al. 2008a) ; lithium/divalproex (Suppes et al. 2009 ; Tohen et al. 2004 ; Vieta et al. 2008b) ; mood stabilizer (Macfadden et al. 2009 ; Zarate & Tohen, 2004) ] was 0.48 (95 % CI 0.35-0.64, p<0.001) (Fig. 3b) . The heterogeneity was moderate with an I 2 score of 35 %. Only for quetiapine in combination with lithium/divalproex was the RR significantly below 1.0 compared to the comparator (p<0.001 and p=0.039, respectively). Together with oxcarbazepine, which had a mean RR of 0.37, the point estimate was also the lowest with a RR of 0.38 (95 % CI 0.29-0.49, p<0.001). Quetiapine represented the major part of the evidence for the RR of depressive relapse in bipolar maintenance with 57 % of the weight in the overall estimate for combination therapy.
RR for all-cause discontinuation
The RRs of all-cause discontinuation during the randomized phase in bipolar maintenance monotherapies were significantly lower than 1.0 for quetiapine, lamotrigine and divalproex (Fig. 4 a) . The finding for olanzapine monotherapy appeared to be an outlier, with a RR of 2.42 (95 % CI 1.51-3.87, p<0.001). However, as this was only based on one study (Tohen et al. 2006) , this estimate is of questionable validity given the results for olanzapine in combination with a mood stabilizer, where the RR in the combination therapy arm was 0.77 (95 % CI 0.62-0.94, p=0.013) compared to mood stabilizer alone (Fig. 4 b) . The olanzapine monotherapy finding is primarily explained by the low rate of discontinuation in the placebo arm (18/36=13 %), rather than a high discontinuation rate in the treatment group (72/225=32 %).
The overall estimate of the RR of discontinuation for monotherapy compared to placebo was 0.93 (95 % CI 0.87-0.99, p=0.024). The heterogeneity was moderate with an I 2 score of 64.0 %. This means that it is very unlikely that observed differences are due to chance alone (Higgins et al. 2003) .
The RRs of discontinuation in bipolar maintenance combination therapies were significantly lower than 1.0 for the olanzapine+lithium/divalproex, quetiapine+ lithium/divalproex and ziprasidone+lithium/divalproex combinations (Fig. 4 b) . Long-acting risperidone in combination with a mood stabilizer had a RR that was not significantly below 1.0 (p=0.056) compared to mood stabilizer alone, but the upper confidence limit was close to 1.0. Compared to mood stabilizer, oxcarbazepine (RR 1.12) and perphenazine (RR 3.16) combination therapies had a RR larger than 1.0 compared to mood stabilizer alone. Both studies were quite small with sample sizes per arm ranging from 18 in the control group of the perphenazine study to 29 patients in the control group of the oxcarbazepine study, but the CI for perphenazine still did not encompass zero (95 % CI 1.03-9.66). However, the rate of discontinuation in the perphenazine arm was not exceptionally high (10/19), rather, the discontinuation rate in the control arm (mood stabilizer alone) was unusually low (3/18). Again, this may be due to the small sample size.
The overall estimate of the RR of discontinuation for combination therapy compared to mood stabilizer was 0.75 (95 % CI 0.62-0.90, p=0.003). The heterogeneity was high with an I 2 score of 73.1 %. Ziprasidone+lithium/divalproex combination therapy had the lowest discontinuation (RR 0.66, p=0.007) .
Discussion
This analysis identified considerable variation in efficacy among bipolar maintenance therapies. In general, the RR of relapse to any mood event was more homogenous across the treatments investigated than if manic/mixed or depressive events were considered separately. All medications (mono-and combination therapy) showed a RR for manic/mixed relapse that was below 1.0, although significance vs. placebo varied among treatments. The risk for depressive relapse was below 1.0 for all monotherapy studies identified except for the risperidone LAI study, although only divalproex and quetiapine showed significance vs. placebo. For the combination therapies, only quetiapine+lithium/divalproex had a RR of depressive relapse significantly below 1.0. Interestingly, the combination therapy quetiapine+lithium/divalproex had a RR for both manic/mixed episode and depressive relapse significantly below 1.0, suggesting that this intervention is effective in preventing relapse to either pole of bipolar illness.
Variation was also observed in the RRs for all-cause discontinuations, with RRs significantly lower than 1.0 for quetiapine monotherapy and combination therapy, divalproex monotherapy, lamotrigine monotherapy, olanzapine combination therapy, and ziprasidone combination therapy. The small sample sizes for some of the studies, however, may have contributed to the higher RR of discontinuation for olanzapine monotherapy and the oxcarbazepine and perphenazine combination therapies. Furthermore, as there may be many different reasons for discontinuationsadministrative reasons, tolerability problems, lack of efficacy or hidden relapses -caution is advised when comparing discontinuation rates across studies.
Population enrichment may contribute to the variation observed between studies. Some studies, for example, those conducted by Bowden et al. (2003) , Calabrese et al. (2000 Calabrese et al. ( , 2003 Calabrese et al. ( , 2005 , Keck et al. (2007) , Suppes et al. (2009 , 2005 , 2006 and Vieta et al. (2008 b) incorporated a stabilization period into the study design after which non-responsive patients or those not considered clinically stable did not participate further. This could be viewed as artificial selection of the most responsive patients, which would limit the comparability between studies. It could also influence the rate of discontinuations as discussed above. However, we did not find any significant differences between the studies in terms of the RR of relapse or discontinuation depending on whether the trials included a stabilization phase or not. The index episode resulting in the initial treatment also differed between studies. In some studies, maintenance treatment was initiated after an acute manic or mixed episode and in other studies after an acute depressive episode. The polarity of the index episode has a relevant impact on the power to prevent further episodes of the same polarity (Calabrese et al. 2004) . For instance, the results for quetiapine showed a higher RR favouring treatment for depressive relapse than for manic/ mixed relapse, while it was the other way around for olanzapine. Hence, at least a partial explanation for this is that the initial episodes were different in the respective studies, where all patients in the olanzapine study had a manic/mixed index episode, while a substantial proportion of the patients in the quetiapine studies had acute depression as index episode. The index episode may therefore be a potential source of heterogeneity in the studies, and will affect the results concerning the relapse rates. Differences in placebo response is an additional factor that may potentially lead to bias in the results, but no significant correlation between the placebo response and the RR of a mood episode was found (Spearman's rank correlation coefficient=x0.051, p=0.836), indicating that the placebo response and the RR are independent. The meta-analysis presented here was intended to have a broader scope than some of the previously published meta-analyses, including many studies that had not been published when previous analyses were carried out. However, despite this the number of studies for some medications, e.g. aripiprazole, was not large. In contrast, lithium was well represented in these studies, reflecting its established position as a maintenance therapy for bipolar disorder. Another limitation of this analysis relates to the comparability of the data from these studies. Differences exist in the definition of a relapse, potentially making some studies more sensitive than others to demonstrations of efficacy. For example, some studies defined relapse as initiation of treatment at the discretion of the treating physician (e.g. Bowden et al. 2003 ; Calabrese et al. 2000 Calabrese et al. , 2003 , some studies included hospitalization in their criteria for relapse (e.g. Bowden et al. 2000b ; Greil et al. 1997 ; Keck et al. 2007) , and others defined relapse according to changes in scales such as the Hamilton Rating Scale for Depression (HAMD), Young Mania Rating Scale (YMRS), Mania Rating Scale (MRS), and Montgomery-Å sberg Depression Rating Scale (MADRS) (e.g. Bowden et al. 2000b ; Calabrese et al. 2005 ; Tohen et al. 2003 Tohen et al. , 2004 Tohen et al. , 2005 Tohen et al. , 2006 Vieta et al. 2008a) . Even where the same scales were used, the cut-off values were not necessarily the same. For example, Tohen et al. (2003 Tohen et al. ( , 2004 Tohen et al. ( , 2005 Tohen et al. ( , 2006 defined relapse to mania as YMRSo15, whereas, Vieta and colleagues defined patients with YMRS>12 as having a recurrence (Vieta et al. 2008a) . A further consideration is that there was no adjustment for study duration and thus exposure to treatment.
The efficacy seen with the atypical antipsychoticsaripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone -as maintenance therapies must be balanced against their side-effect profiles. While it was beyond the scope of this particular meta-analysis to analyse all the safety and tolerability issues involved in bipolar disorder maintenance trials, the data indicate that aripiprazole is associated with tremor, akathisia, dry mouth, and weight gain (Keck et al. 2007) . Trial data for olanzapine show that treatment is associated with somnolence, increased appetite, dry mouth, sedation, weight gain, tremor, asthenia, diarrhoea, hyperprolactinaemia and nausea (Tohen et al. 2005 (Tohen et al. , 2006 . Quetiapine, as a maintenance treatment, is associated with dry mouth, sedation, somnolence, dizziness, constipation, extrapyramidal side-effects, and increases in weight compared to placebo (Suppes et al. 2009 ; Vieta et al. 2008b) . Trial data for risperidone as maintenance treatment indicate that it is associated with weight gain and hyperprolactinaemia (Quiroz et al. 2010) . Long-term ziprasidone treatment is associated with weight gain . There are also concerns of increased risk of metabolic syndrome -characterized by obesity, insulin resistance, hypertension, and dyslipidaemia -with atypical antipsychotics (Baptista et al. 2004) . It is important to be aware, however, that adverse events occurring during maintenance treatment may differ from those observed in patients treated with agents for the first time.
In regard to the question as to whether there is a rationale for distinguishing between drugs with different mechanisms of action as maintenance treatment options, the findings from this meta-analysis suggest a blurring of the lines between drugs with different mechanisms of action and their potential uses for this indication. The findings have confirmed the efficacy of lithium, widely viewed as a 'mood stabilizer ' as effective in the maintenance phase of bipolar disorder. Aripiprazole, olanzapine and quetiapine, which are classed as 'antipsychotics ' also show 'mood stabilizing ' efficacy in patients who have responded to them during an acute episode. These findings suggest that the original drug classification of 'antipsychotic ' may be misleading, and that treatment decisions should be made regarding each individual agent rather than viewing them as particular drug classes.
As for the question of whether any drugs show efficacy against the recurrence of manic/mixed and depressed mood events (i.e. at both poles of bipolar illness), the findings from this analysis show that only combination therapy with quetiapine+lithium/ divalproex was associated with reduced risk for relapse at both the manic/mixed and depressed poles of bipolar illness. 
Conclusions
This meta-analysis indicates that there are several options available for the long-term treatment of bipolar disorder, although considerable variation in the efficacy profile exists among bipolar maintenance therapies. The long-term efficacy of lithium and divalproex has been confirmed, and some atypical antipsychotics, such as aripiprazole, olanzapine, quetiapine, and risperidone are also effective in preventing depressive or manic/mixed relapses. Neither lamotrigine nor oxcarbazepine showed a RR below 1.0 for either manic/mixed or depressive relapse, providing little support for these agents used as monotherapies. For the combination therapies, ziprasidone+lithium/divalproex and risperidone+ lithium/divalproex significantly reduced the risk of a manic relapse, but only quetiapine+lithium/ divalproex significantly reduced risk for relapse at both the manic/mixed and depressed poles of bipolar illness. Interventions with proven efficacy could be considered appropriate options as first-line maintenance treatment but their efficacy will need to be balanced against safety and tolerability issues. 
